Recognition
Recognition

Two Bay Area Partners Honored as Top Women Lawyers

May 16, 2018
Daily Journal
Litigator Karen Silverman and corporate partner Judith Hasko highlighted for their cutting-edge work.

The Daily Journal has selected two Bay Area-based Latham & Watkins partners as among California’s Top Women Lawyers in 2018. The feature, published by California’s leading legal newspaper, annually honors women attorneys who are at the top of their field.

Making her tenth appearance on the Top Women Lawyers list, Karen Silverman is a San Francisco-based litigation partner in Latham’s Global Antitrust & Competition Practice, who currently serves on the firm’s Finance Committee and recently completed a five-year stint as Managing Partner of the San Francisco office. Over the course of her career, Ms. Silverman has cemented her reputation as the go-to lawyer for national and multinational companies seeking counsel on successfully navigating through and securing expedient clearances for complex mergers and acquisitions in jurisdictions around the world. In their profile, the Daily Journal noted the increasingly global nature of Ms. Silverman’s work leading “multibillion-dollar global mergers and acquisition transactions for industry leaders,” adding that she “has her finger on the pulse of a disparate arrange of industries from technology to media to health care.”

Also a frequent Top Women Lawyers honoree, Silicon Valley corporate partner and Global Chair of Latham's Life Sciences Licensing Group Judith Hasko was selected for her groundbreaking strategic licensing work, devising cutting-edge transaction paradigms which are enabling life sciences companies to secure crucial funding and technologies for the development and commercialization of drug therapies and medical device innovations that save lives. In their profile, the Daily Journal highlighted Ms. Hasko’s work guiding “longtime global client Prothena Corp., based in Dublin, Ireland, in its strategic collaboration with Celgene…valued at up to $2.2 billion in milestone and other payments to develop new therapies for neurodegenerative diseases.”